BioSpace News Archive

Capricor Therapeutics announced that the Company will present 24-month safety and efficacy results from its ongoing HOPE-2 open-label extension study with its lead asset, CAP-1002, for the treatment of Duchenne Muscular Dystrophy at this year’s Parent Project Muscular Dystrophy Annual Conference.

PharmaLogic Holdings Corp. and Evergreen Theragnostics, Inc., announced their agreement for PharmaLogic to prepare, sell, and distribute OCTEVY™, if approved by the United States Food & Drug Administration, to their extensive network of PET customers across the country.

Cardio Diagnostics Holdings, Inc, a pioneer of artificial intelligence-driven precision cardiovascular medicine tests, announced the publication of groundbreaking research in the journal Genes.

The first U.S.-based company with promising proof of concept for intranasal/inhaled adenovirus vaccines, Moat Biotechnology Corporation, announces it has raised more than $6.5 million in its first close of funding.

Adaptive Phage Therapeutics announced that it has received a $12 million upfront investment from funds managed by Deerfield Management and the AMR Action Fund as part of a new $24 million total investment in a Series B1 round that is targeting $30 million in aggregate.

QIAGEN announced that its variant interpretation and reporting software, QIAGEN Clinical Insight Interpret, is being deployed as a part of a national initiative in Denmark to offer sequencing-based solutions for cancer patients.

PepGen Inc. (Nasdaq: PEPG) today announced that while it awaits receipt of an official clinical hold letter from the U.S. Food and Drug Administration (FDA), the Company is withdrawing its prior guidance with respect to the timeline for initiating a Phase 1 study of PGN-EDODM1 in patients with myotonic dystrophy type 1 (DM1) in the first half of 2023 in any geography.

Zynerba Pharmaceuticals, Inc. announced that it has adjourned its 2023 Annual Meeting of Stockholders solely with respect to Proposal 2 set forth in its Definitive Proxy Statement filed with the Securities and Exchange Commission on April 21, 2023.

Kura Oncology, Inc. announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell $100,000,000 of shares of its common stock.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. District Court for the District of New Jersey ruled in favor of the company and found that Merck correctly calculated the Patent Term Extension period for the primary patent related to BRIDION® (sugammadex).